Surmodics, Inc.
Surmodics, Inc. (SRDX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
srdx · pe ratio · data through Sep 30, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Surmodics, Inc. (SRDX) measures how much investors pay for each dollar of the company's trailing earnings. SRDX's current PE ratio of N/A is calculated by dividing its stock price of $42.98 by its TTM earnings per share of -$0.99.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-09-30
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%38.5x
MedianQ3 · 75%469.6x
Max
At N/A, SRDX's current P/E is lower than in 0% of its annual fiscal year readings over the past 13 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Surmodics, Inc.You SRDX | $615M | N/A | — | -$0.99 |
 Bioventus Inc. BVS | $606M | 21.81x | — | $0.34 |
 CeriBell, Inc. CBLL | $688M | N/A | — | -$1.46 |
 Cross Country Healthcare, Inc. CCRN | $426M | N/A | — | -$2.93 |
 OrthoPediatrics Corp. KIDS | $468M | N/A | — | -$1.69 |
 Standard BioTools Inc. LAB | $314M | N/A | — | -$0.20 |
 RxSight, Inc. RXST | $205M | N/A | — | -$0.95 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-09-30Latest FY2024 | — | $-0.82 | — | |
2023-09-30 FY2023 | — | $-0.11 | — | |
2022-09-30 FY2022 | — | $-1.96 | — | |
2021-09-30 FY2021 | 180.63x | $0.31 | -61.5% | |
2020-09-30 FY2020 | 469.55x | $0.08 | +482.1% | |
2019-09-30 FY2019 | 80.67x | $0.57 | — | |
2018-09-30 FY2018 | — | $-0.34 | — | |
2017-09-30 FY2017 | 103.86x | $0.30 | +165.1% | |
2016-09-30 FY2016 | 39.17x | $0.77 | +85.1% | |
2015-09-30 FY2015 | 21.16x | $1.03 | +2.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Surmodics, Inc. (SRDX) measures how much investors pay for each dollar of the company's trailing earnings. SRDX's current PE ratio of N/A is calculated by dividing its stock price of $42.98 by its TTM earnings per share of -$0.99.
Frequently asked questions
SRDX pe ratio · 6 questionsSRDX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $42.98 and TTM EPS of -$0.99. Data sourced from Financial Modeling Prep via SRDX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Surmodics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09